BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38849683)

  • 1. ASO Visual Abstract: Neoadjuvant Chemotherapy Improves Feasibility of Larynx Preservation and Prognosis for Resectable Locally Advanced Cervical Esophageal Cancer.
    Kubo Y; Nozaki R; Igaue S; Utsunomiya D; Kubo K; Yamamoto S; Kurita D; Kashihara T; Ishiyama K; Honma Y; Oguma J; Kato K; Daiko H
    Ann Surg Oncol; 2024 Jun; ():. PubMed ID: 38849683
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant Chemotherapy Improves Feasibility of Larynx Preservation and Prognosis in Resectable Locally Advanced Cervical Esophageal Cancer.
    Kubo Y; Nozaki R; Igaue S; Utsunomiya D; Kubo K; Yamamoto S; Kurita D; Kashihara T; Ishiyama K; Honma Y; Oguma J; Kato K; Daiko H
    Ann Surg Oncol; 2024 May; ():. PubMed ID: 38755340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of neoadjuvant immunotherapy combined with chemotherapy in the treatment of larynx preservation in locally advanced hypopharyngeal squamous cell carcinoma].
    Wu J; Hu G; Li M; Wang Z; Ma W; Wang X; Zhu J; Pan M; Zeng Q
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Sep; 37(9):715-720;728. PubMed ID: 37830119
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant Chemoradiotherapy and Larynx-Preserving Surgery for Cervical Esophageal Cancer.
    Dai KY; Yu YC; Leu YS; Chi CW; Chan ML; Tsai CH; Lin HC; Huang WC; Chen YJ
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32024132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis.
    Wang J; Zhang K; Liu T; Song Y; Hua P; Chen S; Li J; Liu Y; Zhao Y
    Front Oncol; 2022; 12():974684. PubMed ID: 36158679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer.
    Dai H; Liu M; Li X; Li T; Huang W; Liao J; Li Y; Fang S
    World J Surg Oncol; 2022 Aug; 20(1):267. PubMed ID: 36008813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Shen D; Chen Q; Wu J; Li J; Tao K; Jiang Y
    J Gastrointest Oncol; 2021 Feb; 12(1):1-10. PubMed ID: 33708420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
    Chao L; Liu J; Chen Y; Fan Y; Guo S; Zhang S
    Thorac Cancer; 2024 Mar; 15(8):622-629. PubMed ID: 38316630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.
    Zhang H; Zhang Z; Yang L; Wu B; Chen Y; He H; Li C; Lin W; Lin J
    J Thorac Dis; 2023 Mar; 15(3):1279-1288. PubMed ID: 37065590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
    Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
    World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
    Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
    J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
    He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
    Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Multicenter Phase II Study on the Feasibility and Efficacy of S-1 and Oxaliplatin Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Sakamoto Y; Morohashi H; Miura T; Tsutsumi S; Takahashi S; Hirama K; Wakiya T; Hakamada K
    Dis Colon Rectum; 2022 May; 65(5):663-671. PubMed ID: 33833145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic strategy for marginally resectable esophageal cancer].
    Koyanagi K; Ozawa S
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1241-5. PubMed ID: 21829059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
    He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
    Front Immunol; 2022; 13():853922. PubMed ID: 35720312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASO Visual Abstract: Influence of Neoadjuvant Immunotherapy-Chemotherapy on Perioperative Outcomes in Locally Advanced Esophageal Adenocarcinoma.
    Nevo Y; Tankel J; Zao H; Ramirez J; Cools-Lartigue J; Muller C; Alcindor T; Ferri L
    Ann Surg Oncol; 2024 Apr; ():. PubMed ID: 38679680
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial.
    Ou X; Zhai R; Wei W; Chen J; Ou D; Liao T; Xu T; Zhu Y; Wang Y; Huang S; Shi R; Wu B; Chen T; Li Y; Yang Z; Zhou C; Liu Y; Jiang Z; Zeng M; Liu X; Ji D; Ying H; Zhang Z; Hu C; Lu X; Ji Q; He X; Wang Y
    Clin Cancer Res; 2024 Jan; 30(2):344-355. PubMed ID: 37955629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.